JP2017520540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017520540A5 JP2017520540A5 JP2016571359A JP2016571359A JP2017520540A5 JP 2017520540 A5 JP2017520540 A5 JP 2017520540A5 JP 2016571359 A JP2016571359 A JP 2016571359A JP 2016571359 A JP2016571359 A JP 2016571359A JP 2017520540 A5 JP2017520540 A5 JP 2017520540A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- salt
- radiolabeled
- halogen atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims 27
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 22
- 125000001424 substituent group Chemical group 0.000 claims 15
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 6
- 125000002393 azetidinyl group Chemical group 0.000 claims 6
- 125000002950 monocyclic group Chemical group 0.000 claims 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 6
- 125000003277 amino group Chemical group 0.000 claims 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 3
- 238000003384 imaging method Methods 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 3
- 102000020038 Cholesterol 24-Hydroxylase Human genes 0.000 claims 2
- 108091022871 Cholesterol 24-Hydroxylase Proteins 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- UTHXOPCOQREWLE-GJQNQZCXSA-N (3-(18F)fluoranylazetidin-1-yl)-[1-[4-(4-fluorophenyl)pyrimidin-5-yl]piperidin-4-yl]methanone Chemical compound [18F]C1CN(C1)C(=O)C1CCN(CC1)C=1C(=NC=NC=1)C1=CC=C(C=C1)F UTHXOPCOQREWLE-GJQNQZCXSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- BTVHVVUBTCVPAG-AWDFDDCISA-N [1-[4-(4-bromopyrazol-1-yl)pyridin-3-yl]piperidin-4-yl]-(3-(18F)fluoranylazetidin-1-yl)methanone Chemical compound BrC=1C=NN(C=1)C1=C(C=NC=C1)N1CCC(CC1)C(=O)N1CC(C1)[18F] BTVHVVUBTCVPAG-AWDFDDCISA-N 0.000 claims 1
- TUBCOLWOJLEAOC-AWDFDDCISA-N [1-[4-(4-chloropyrazol-1-yl)pyridin-3-yl]piperidin-4-yl]-(3-(18F)fluoranylazetidin-1-yl)methanone Chemical compound ClC=1C=NN(C=1)C1=C(C=NC=C1)N1CCC(CC1)C(=O)N1CC(C1)[18F] TUBCOLWOJLEAOC-AWDFDDCISA-N 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 238000002059 diagnostic imaging Methods 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462009526P | 2014-06-09 | 2014-06-09 | |
| US62/009,526 | 2014-06-09 | ||
| PCT/JP2015/067100 WO2015190613A1 (en) | 2014-06-09 | 2015-06-08 | Radiolabeled compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017520540A JP2017520540A (ja) | 2017-07-27 |
| JP2017520540A5 true JP2017520540A5 (OSRAM) | 2018-06-21 |
| JP6533799B2 JP6533799B2 (ja) | 2019-06-19 |
Family
ID=53610936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016571359A Active JP6533799B2 (ja) | 2014-06-09 | 2015-06-08 | 放射標識された化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9963443B2 (OSRAM) |
| EP (1) | EP3152198B1 (OSRAM) |
| JP (1) | JP6533799B2 (OSRAM) |
| CN (1) | CN106573916A (OSRAM) |
| CA (1) | CA2951521A1 (OSRAM) |
| WO (1) | WO2015190613A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015007495A (es) * | 2012-12-11 | 2015-09-04 | Takeda Pharmaceutical | Compuesto heterociclico. |
| ES2941895T3 (es) | 2014-11-25 | 2023-05-26 | Bristol Myers Squibb Co | Métodos y composiciones para radioetiquetado con 18F del dominio de fibronectina tipo (III) |
| CA2969067A1 (en) | 2014-11-25 | 2016-06-02 | Bristol-Myers Squibb Company | Novel pd-l1 binding polypeptides for imaging |
| EP3463486A1 (en) | 2016-06-01 | 2019-04-10 | Bristol-Myers Squibb Company | Pet imaging with pd-l1 binding polypeptides |
| WO2017210335A1 (en) * | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
| WO2020027344A1 (en) * | 2018-08-03 | 2020-02-06 | Takeda Pharmaceutical Company Limited | Ch24h inhibitors for mdd use |
| US20210346366A1 (en) * | 2018-09-20 | 2021-11-11 | Takeda Pharmaceutical Company Limited | Ch24h inhibitors for pain use |
| CN111436396A (zh) * | 2020-04-24 | 2020-07-24 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 大鼠恐惧应激与气态污染物复合暴露模型的建立方法 |
| WO2024035925A2 (en) * | 2022-08-12 | 2024-02-15 | Emory University | N-cyclopropyl-1-(4-(4-(fluoro-18f)phenyl)pyrimidin-5-yl)-n-methylpiperidine-4-carboxamide and uses in pet imaging |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11514333A (ja) | 1995-03-14 | 1999-12-07 | プレーシス ファーマスーティカルズ インコーポレイテッド | アミロイドの凝集の調節剤 |
| EP0929574B1 (en) | 1996-08-27 | 2005-06-29 | Praecis Pharmaceuticals Incorporated | MODULATORS OF beta-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS |
| AU5773500A (en) | 1999-06-28 | 2001-01-31 | Board Of Trustees Of The University Of Illinois, The | Inhibitors of memapsin 2 and use thereof |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| WO2001087834A1 (en) | 2000-05-16 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Melanin-concentrating hormone antagonist |
| WO2004078732A1 (fr) * | 2003-01-28 | 2004-09-16 | Aventis Pharma S.A. | Produits n-aryl-heteroaromatiques, compositions les contenant et utilisation |
| US7807671B2 (en) * | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
| WO2007139946A2 (en) * | 2006-05-25 | 2007-12-06 | University Of Tennessee Research Foundation | Gpcr ligands identified by computational modeling |
| GB0903493D0 (en) * | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
| WO2010110400A1 (ja) | 2009-03-26 | 2010-09-30 | 武田薬品工業株式会社 | 複素環化合物 |
| ES2663370T3 (es) * | 2011-08-22 | 2018-04-12 | Takeda Pharmaceutical Company Limited | Compuestos radiomarcados y su uso como radiotrazadores para imagenología cuantitativa de la fosfodiesterasa (PDE10A) en mamíferos |
| PT2763979T (pt) | 2011-10-07 | 2019-04-12 | Takeda Pharmaceuticals Co | Compostos de 1-arilcarbonil-4-oxi-piperidina úteis para o tratamento de doenças neurodegenerativas |
| CN104136420A (zh) * | 2011-12-15 | 2014-11-05 | 通用电气健康护理有限公司 | 作为tau病理学的成像探针的杂环化合物 |
| US9296746B2 (en) | 2012-10-16 | 2016-03-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| MX2015007495A (es) * | 2012-12-11 | 2015-09-04 | Takeda Pharmaceutical | Compuesto heterociclico. |
| EP2982666B1 (en) | 2013-04-04 | 2019-08-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP6272833B2 (ja) | 2013-04-04 | 2018-01-31 | 武田薬品工業株式会社 | 複素環化合物 |
| US9169243B2 (en) * | 2013-12-20 | 2015-10-27 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
| WO2015099196A1 (en) * | 2013-12-26 | 2015-07-02 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors |
-
2015
- 2015-06-08 CA CA2951521A patent/CA2951521A1/en not_active Abandoned
- 2015-06-08 US US15/316,937 patent/US9963443B2/en active Active
- 2015-06-08 EP EP15738487.6A patent/EP3152198B1/en active Active
- 2015-06-08 WO PCT/JP2015/067100 patent/WO2015190613A1/en not_active Ceased
- 2015-06-08 JP JP2016571359A patent/JP6533799B2/ja active Active
- 2015-06-08 CN CN201580042832.2A patent/CN106573916A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017520540A5 (OSRAM) | ||
| JP2020502092A5 (OSRAM) | ||
| JP2019518766A5 (OSRAM) | ||
| JP2016535772A5 (OSRAM) | ||
| JP2016505614A5 (OSRAM) | ||
| JP2012092103A5 (OSRAM) | ||
| JP2016503793A5 (OSRAM) | ||
| JP2014506907A5 (OSRAM) | ||
| JP2014051526A5 (OSRAM) | ||
| JP2017535614A5 (OSRAM) | ||
| JP2016534134A5 (OSRAM) | ||
| JP2015508103A5 (OSRAM) | ||
| JP2017513894A5 (OSRAM) | ||
| JP2015537020A5 (OSRAM) | ||
| JP2016531868A5 (OSRAM) | ||
| JP2014515008A5 (OSRAM) | ||
| JP2017511794A5 (OSRAM) | ||
| JP2016506958A5 (OSRAM) | ||
| JP2017508782A5 (OSRAM) | ||
| JP2014526533A5 (OSRAM) | ||
| JP2016529319A5 (OSRAM) | ||
| JP2016529315A5 (OSRAM) | ||
| JP2019500374A5 (OSRAM) | ||
| JP2017529365A5 (OSRAM) | ||
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий |